NAYA Biosciences Corp - NAYA Operating Margin

Corporate company logo of NAYA Biosciences (NAYA)

The absence of commercial revenue due to the early stages of monoclonal drug research shifts NAYA Biosciences (NAYA) growth into the realm of R&D expenditures. The operating profit margin reflects this specificity, where -90.90 represents the latest value. Business stability relies on innovative bioplatforms and mergers in the US, although risks of test failures and a total dependence on speculative investments persist.

NAYA: NAYA Biosciences Inc. Profitability of Operations 07/04/2022 - 04/28/2025

NAYA (NAYA Biosciences): analytical breakdowns and indicator data

- stock quotes and analyst forecast:
Comprehensive company analysis:NAYA Biosciences Corp, NAYA
Core merchandise of NAYA Biosciences Corp

For NAYA Biosciences, which invests in a staff of biologists and clinical trials, the operating margin serves as a metric for the efficiency of R&D cost management. An analysis of the EBIT margin allows for an assessment of the share of operating profit before taxes and interest, demonstrating how successfully the innovative business model converts resources into revenue while excluding the impact of debt load and one-off market fluctuations.

Competitor analysis

Operating Profitability BeiGene Ltd|Halozyme Therapeutics - Operating Profit Margin|Operating Sales Margin RVMD (Revolution Medicines Corp)|Operating Profit Ratio AAPG|Operating Profitability CG Oncology Therapeutics CGON|Operating Profit Rate URGN|BCAX: Operating Sales Margin|PSNL: Operating Profitability|Erasca (ERAS) - Operating Profitability|DCTH - Profitability of Operations|YMAB (Y-mAbs Corp) - Operating Margin|Operating Sales Margin Aura Biosciences (AURA)|Operating Profitability Candel Therapeutics Inc. (CADL)|Operating Sales Margin Accuray, Inc. ARAY|Operating Profitability sellaslifesciences.com SLS|Operating Profit Rate ACTU|CTOR - Operating Profitability|Profitability of Operations tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Operating Profitability|FATE: Operating Profit Ratio|WHWK (Aadi Bioscience, Inc.) - Operating Margin|TCRX (TScan Therapeutics) - Operating Profit Ratio|Operating Profitability Champions Oncology (CSBR)|Profitability of Operations XBiotech USA|Operating Profitability CEL-SCI CVM|OS Therapies, Inc. (OSTX) - Operating Return on Sales|RADX - Operating Profitability|ARTV - Operating Margin|Adlai Nortye Ltd (ANL) - Operating Profitability|Veru Pharma - Operating Profit Rate|Operating Profitability Tempest Therapeutics Corp|Return on Sales by Operating Profit XLO (Xilio Therapeutics, Inc.)|Operating Margin RENB|MURA (Mural Oncology) - Operating Profit Rate|Operating Margin KAPA (Kairos Pharma Ltd)|OKUR: Return on Sales by Operating Profit|GDTC: Operating Sales Margin|CRIS - Operating Margin|APLM: Operating Margin|Operating Return on Sales tharimmune.com (THAR)|ADVB (Advanced Biomed Corp) - Operating Margin|Operating Margin Genprex Inc.|Operating Margin CLDI|Operating Sales Margin Sunshine Biopharma, Inc. SBFM|Operating Margin XBIO (Xenetic Biosciences)|Operating Profit Rate SLRX|PPBT - Operating Profitability|AONC (aoncology.com) - Return on Sales by Operating Profit|BGNE: Operating Margin|Checkpoint Therapeutics Inc (CKPT) - Operating Margin|ELEV (Elevation Oncology Inc.) - Operating Margin|icadmed.com (ICAD) - Profitability of Operations|Operating Margin IKNA|NTBL (Notable Labs) - Operating Profit Rate|Operating Margin VIRX (Viracta Therapeutics)|Profitability of Operations MorphoSys AG (MOR)|Ascentage Pharma Group International - Operating Margin